Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma—2 case reports and a brief review

Journal of Gastrointestinal Oncology

Viraj Lavingia²  Marwan Fakih¹ 

[1] Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, USADepartment of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, USADepartment of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, USA;Department of Medicine, Apollo Cancer Hospital, Jubilee Hills, Hyderabad, IndiaDepartment of Medicine, Apollo Cancer Hospital, Jubilee Hills, Hyderabad, IndiaDepartment of Medicine, Apollo Cancer Hospital, Jubilee Hills, Hyderabad, India

关键词: Intrahepatic cholangiocarcinoma (ICC);    BRAF;    MEK;    dabrafenib;    trametinib;   

DOI  :  10.21037/jgo.2016.09.13

学科分类：肿瘤学

来源: Pioneer Bioscience Publishing Company

【 授权许可】

Unknown